New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA)

Intrahepatic cholangiocarcinoma (iCCA) is a malignant neoplasm of the biliary tract, the incidence of which has increased in recent years. The etiopathogenesis is not fully elucidated, but the greatest association has been shown with inflammatory changes within the biliary tract. Surgical treatment...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2023-06, Vol.59 (6), p.1174
Main Authors: Becht, Rafał, Wasilewicz, Michał P
Format: Article
Language:English
Subjects:
Adjuvant treatment
Apoptosis
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - genetics
Bile Ducts, Intrahepatic
Brain cancer
Cancer
Cancer therapies
Chemotherapy
Cholangiocarcinoma
Cholangiocarcinoma - genetics
Combined Modality Therapy
Health aspects
Humans
Immunotherapy
intrahepatic cholangiocarcinoma
Ipilimumab
Kinases
Medical prognosis
molecular diagnostics
neoadjuvant and adjuvant chemotherapy
Response rates
Review
Surgery
targeted therapies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intrahepatic cholangiocarcinoma (iCCA) is a malignant neoplasm of the biliary tract, the incidence of which has increased in recent years. The etiopathogenesis is not fully elucidated, but the greatest association has been shown with inflammatory changes within the biliary tract. Surgical treatment is the main therapeutic modality; however, less than 30% of its are resectable at diagnosis, with the majority of patients requiring systemic treatment. Chemotherapy with capecitabine is the standard adjuvant therapy. For patients with inoperable tumors or metastatic lesions, chemotherapy alone or in combination with immunotherapy (durvalumab, pembrolizumab) is used. There is a need to provide systemic treatment in patients with progression after first-line treatment in good performance status. New therapeutic pathways for the treatment of this tumor type are still being identified with new emerging potential targets such as isocitrate dehydrogenase (IDH), fibroblast growth factor receptor 2 (FGFR2), or BRAF mutation.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina59061174